Sabby Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Sabby Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,120	Closed	-$357K	–	84
2019 Q3	$357K	Buy	1,120 +631	+129%	+$2.1K	0.19%	53
2019 Q2	$17K	Buy	+489	New	+$1.73K	0.02%	83

Other funds holding ORMP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sabby Management's ORMP Position: Q4 2021 in Review

Sabby Management sold out of Oramed Pharmaceuticals (ORMP) in Q4 2021, closing a stake of 40,344 shares — an estimated $887K sold.

Sabby Management first reported a position in ORMP in Q2 2015 and held it in 8 quarters. The position peaked at $3.88M in Q3 2018. 116 funds tracked by Wall St. Rank hold ORMP as of Q4 2021.

Sabby Management reported no remaining Oramed Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Sabby Management sold 40,344 Oramed Pharmaceuticals shares in Q4 2021, an estimated $887K.
Sabby Management first reported a position in Oramed Pharmaceuticals in Q2 2015 and held it in 8 quarters.
Sabby Management's Oramed Pharmaceuticals position peaked at $3.88M in Q3 2018.
116 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2021.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.